Overview

The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Azithromycin has high rates of clinical response and eradication, wide spectrum of activity, so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community acquired pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Azithromycin